|Dr. Mehdi Gasmi||Pres & Chief Scientific Officer||688.43k||N/A||1967|
|Dr. Mitchell H. Finer||Co-Founder & Director||42.5k||N/A||1959|
|Dr. Amber Salzman||Consultant||904.99k||N/A||1962|
|Ms. Leone D. Patterson||CEO, CFO & Director||N/A||N/A||1963|
|Ms. Katherine Bock||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Adverum Biotechnologies, Inc.’s ISS Governance QualityScore as of March 1, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 10.